KALA BIO to Participate in Upcoming Investor Conferences in August
03 August 2023 - 6:01AM
KALA BIO, Inc. (Nasdaq:KALA), a clinical-stage biopharmaceutical
company dedicated to the research, development and
commercialization of innovative therapies for rare and severe
diseases of the eye, today announced that management will
participate in the following investor conferences in August 2023:
2023 Wedbush PacGrow Healthcare ConferenceDate:
Wednesday, August 9, 2023Company management will be available for
1x1 investor meetings in New York, NY.
H.C. Wainwright 3rd
Annual Ophthalmology Virtual ConferenceDate:
Wednesday, August 16, 2023A pre-recorded presentation will be made
available beginning Wednesday, August 16, 2023 at 7:00 a.m. ET.
Sidoti Micro Cap ConferenceDate: Thursday,
August 17, 2023Company management will present virtually at 1:00
p.m. ET.
To access the webcast and subsequent archived recording of the
H.C Wainwright and Sidoti presentations, please visit the
“Presentations” section of the Kala website at www.kalarx.com.
About KALA BIO, Inc.
KALA BIO is a clinical-stage biopharmaceutical company dedicated
to the research, development and commercialization of innovative
therapies for rare and severe diseases of the eye. KALA BIO’s
biologics-based investigational therapies utilize KALA BIO’s
proprietary mesenchymal stem cell secretome (MSC-S) platform. KALA
BIO’s lead product candidate, KPI-012, is a human MSC-S, which
contains numerous human-derived biofactors, such as growth factors,
protease inhibitors, matrix proteins and neurotrophic factors that
can potentially correct the impaired corneal healing that is an
underlying etiology of multiple severe ocular diseases. KPI-012 is
currently in clinical development for the treatment of persistent
corneal epithelial defect (PCED), a rare disease of impaired
corneal healing, for which it has received Orphan Drug and Fast
Track designations from the U.S. Food and Drug Administration. KALA
BIO is also targeting the potential development of KPI-012 for the
treatment of Limbal Stem Cell Deficiency and other rare corneal
diseases that threaten vision and has initiated preclinical studies
to evaluate the potential utility of its MSC-S platform for retinal
degenerative diseases, such as Retinitis Pigmentosa and Stargardt
Disease. For more information on KALA BIO, please visit
www.kalarx.com.
Investor Contact:
Hannah Deresiewiczhannah.deresiewicz@sternir.com212-362-1200
KALA BIO (NASDAQ:KALA)
Historical Stock Chart
From Apr 2024 to May 2024
KALA BIO (NASDAQ:KALA)
Historical Stock Chart
From May 2023 to May 2024